Trial Profile

A Phase 1b/2 Multisite Dose- and Regimen-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (NHL)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs WTX-330 (Primary)
Indications Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Werewolf Therapeutics

08 May 2025 According to a Werewolf Therapeutics media release, company initiated patient dosing in this Phase 1b/2 clinical trial.
28 Apr 2025 Status changed from planning to recruiting.
11 Mar 2025 According to a Werewolf Therapeutics media release, clinical trial is expected to be initiated by the end of the first quarter of 2025, Pending data from Phase 1/2 dose- and regimen-finding trial, anticipate opening expansion arms in selected tumor types.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com